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Early Treatment Diabetic Retinopathy Study; IVAN, Inhibit VEGF in Age-Related 
Choroidal Neovascularisation; logMAR, logarithm of the minimum angle of 
resolution; nAMD, neovascular age-related macular degeneration; NHS, National 
Health Service; OCT, optical coherence tomography; PRN, pro re nata; TFI, 
treatment-free intervals; UK, United Kingdom; VA, visual acuity; VEGF, vascular 
endothelial growth factor   
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SUBTITLE 
The likelihood of retreatment with ranibizumab for neovascular age-related macular 
degeneration reduces as the time without treatment increases. Nearly a third of eyes 
require retreatment within the next 12-months despite remaining injection-free for 12-
months.  
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ABSTRACT 
Background/aims: To study the time to retreatment in eyes with neovascular age-
related macular degeneration (nAMD) that had been treatment-free for intervals of 3, 
6, 9 and 12 months during the maintenance phase of ranibizumab therapy within the 
UK National Health Service.   
 
Methods: In this multicentre national nAMD database study, structured data were 
collected from 14 centres (involving 12,951 eyes receiving 92,976 ranibizumab 
injections). Patients were treated with 3 fixed, monthly injections in a loading phase 
of treatment, followed by pro-re-nata retreatment regimen in a maintenance phase. 
Eyes with a treatment-free interval (TFI) of 3, 6, 9, or 12 months in the maintenance 
phase were identified and the time to retreatment after these TFIs was determined.  
 
Results: The time to retreatment for the 20th and 50th centile was 0.58/2.54 months 
after a 3-month TFI, 2.07/9.62 months after a 6-month TFI, 3.69/15.84 months after a  
9-month TFI and 5.90/22.49 months after 12-month TFI. Following a TFI of 3, 6, 9 
and 12 months, 68%, 44%, 31% and 21% of eyes required retreatments after an 
additional 6 months of follow-up respectively. Similarly, after 12-months of follow-
up, 77%, 56%, 43% and 34% of these eyes required retreatment.  
 
Conclusions: This study provides times to retreatment in eyes with nAMD that have 
been treatment-free for intervals of 3-12 months and demonstrates the likelihood of 
repeat therapy within the next year, even after a treatment-free interval of 12 months. 
These outcomes can help plan appropriate follow-up intervals for patients who have 
been treatment-free for intervals of up to 12 months. 
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INTRODUCTION 
With the approval of ranibizumab for neovascular AMD (nAMD) in 2008 by the UK 
National Institute of Health and Clinical Excellence (NICE), ranibizumab has been 
used exclusively in the National Health Service (NHS), until the recent emergence of 
aflibercept. In accordance with the original European product licence, ranibizumab 
was administered in routine clinical practice as a loading phase of 3 injections, given 
at monthly intervals, followed by as needed or pro re nata (PRN) regimen if active 
disease was detected at regular assessment visits, based on visual acuity, slit lamp 
examination and retinal imaging with optical coherence tomography (OCT), a 
regimen largely based on the Prospective Optical Coherence Tomography imaging of 
patients with Neovascular AMD Treated with Intra-ocular Ranibizumab (PrONTO) 
study.[1,2] Although the Avastin (bevacizumab) for choroidal neovascular age-related 
macular degeneration trial (ABC Trial), Comparison of Age-Related Macular 
Degeneration Treatments Trials (CATT) and Inhibit VEGF in Age-Related Choroidal 
Neovascularization (IVAN) trials have subsequently shown that this approach gives 
comparable outcomes, no real-world studies have achieved the outcomes 
demonstrated by clinical trials.[3-11]  
 
There is a paucity of high-quality data regarding the likelihood of retreatment with 
ranibizumab in eyes that have remained treatment-free for variable period of time. It 
is essential to evaluate this to plan the frequency of follow-up in such patients and 
help reduce the demand on healthcare services, which are already overburdened, 
without compromising the quality of care.  
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Appropriately designed and used electronic medical record (EMR) systems offer the 
ability to capture and pool a large proportion or even all treated patient outcomes to 
assess the real-life clinical outcomes. They have the benefit that all data are collected 
as a by-product of routine clinical practice, often in the context of paperless clinics 
and, in the UK, have been designed to mandate capture of a predefined minimum 
dataset. Therefore, they approximate a clinical trial electronic case report form. The 
UK Neovascular AMD database project was developed to collate data from multiple 
centres using EMRs in routine clinical practice to understand real-world outcomes of 
ranibizumab therapy for nAMD. The aims of this specific report were to look at the 
time to retreatment in eyes with nAMD that have remained treatment-free during the 
maintenance phase of ranibizumab therapy (after three fixed monthly injections)and 
to assess their visual outcome.   
 
MATERIALS AND METHODS 
Study Design 
Two EMR systems from different companies in the UK are known to collect nAMD 
treatment and assessment data. Sites known to make comprehensive use of these 
systems were contacted; however, only sites using 1 EMR system met the deadline 
given with regard to permissions to extract data. All data therefore were derived from 
1 supplier (Medisoft Ophthalmology, Medisoft Limited, Leeds, UK). The lead 
clinician and Caldicott Guardian (who oversees data protection) at each centre gave 
written approval for the data extraction. Patient identifiers were stripped out 
completely and site and clinician data were pseudo-anonymised; on this basis, an 
ethics committee determined that formal ethics approval was not required. Further 
details on data entry into EMR have been published in our previous papers.[12-14] 
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This study was conducted in accordance with the declaration of Helsinki and the UK's 
Data Protection Act. 
 
Settings 
Fourteen NHS hospitals that deliver ranibizumab AMD treatment services in England 
and Northern Ireland submitted data to this study. Following NICE approval for the 
use of ranibizumab for nAMD in the NHS in August 2008, all sites used this drug 
exclusively, although before this date, some sites offered treatment with bevacizumab. 
The study was initiated on February 1, 2012 and data extraction was performed by 
April 2, 2012.  
 
Variables 
Analysis was restricted to eyes that had remained treatment-free for variable durations 
(3, 6, 9 and 12 months) during the maintenance phase of ranibizumab treatment 
following three fixed monthly injections (loading phase). The treatment-free interval 
could start anytime during this maintenance phase. Patients undergoing combined 
therapies or having prior bevacizumab in either eye were excluded, as were patients 
who had received prior laser based therapies.  
 
Although this study itself is retrospective, the structured dataset used for the 
management of nAMD in the EMR system was deﬁned and set up before the date of 
ﬁrst data collection in this study. This contrasts with a conventional retrospective 
chart review with unstructured data and is more akin to the electronic case report form 
used in clinical trials, but with the data captured as a by-product of routine clinical 
care.   
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Data Sources and Measurements 
In this report, the best-measured visual acuity (VA) was the best VA with refraction 
or habitual correction, pinhole, or both as measured on an Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart. The vast majority of sites measured VA with 
habitual correction rather than best-corrected refracted VA at all time points. Analysis 
for eyes with very low VA was undertaken by substituting counting fingers, hand 
movements, and light perception with 2.0, 2.3, and 2.7, respectively.[15]  
 
Follow-up 
All patients received a loading phase of 3 intravitreal injections of 0.5 mg 
ranibizumab (Lucentis, Novartis Pharma AG, Basel, Switzerland) given at monthly 
intervals, followed by PRN treatment if active disease was detected at scheduled 
assessment visits. 
 
During the maintenance phase, some centres ran a 2-stop service (assessment and 
treatment on different days). For ease of analysis and to allow standardised 
comparison of follow-ups between centres, follow-ups within a ± 2-week block were 
regarded as single visit.  
 
All eyes had OCT examinations at practically every visit. Many sites did not perform 
OCTs at the time of the second and third injection visits (of the loading phase) 
because the patients were definitely receiving injections, but thereafter, OCT 
assessments were performed at every intended monthly follow-up.  
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‘Retreatment’ with ranibizumab after a certain treatment-free period was left to the 
discretion of individual clinicians as per The Royal College of Ophthalmologists’ 
guidance which recommends retreatment if patients showed any sign of disease 
activity. Activity was denoted by new or persistent retinal, subretinal, or sub-RPE 
fluid or haemorrhage as determined clinically and/or on OCT, lesion growth on FFA 
(morphological), and/or deterioration of vision (functional).[16]   
 
Statistical Methods 
Data were extracted from the EMR for patients who had received at least 1 
intravitreal injection of ranibizumab for nAMD. STATA software version 11 (Stata 
Corp, College Station, TX), SPSS software version 19 (SPSS, Inc, Chicago IL) were 
used to generate basic demographics and outcomes (AT, WX). To check for errors in 
combining and reshaping large datasets, primary outcomes were verified in statistical 
software databases separately by the two of the authors (AT, AL) and statisticians 
(CB, WX). R software (version 3.0.2) and Perl (version v5.16.2) were used to 
combine, clean, reshape, merge, recode, and analyse data (AL) used in the primary 
analysis in this manuscript.  
 
RESULTS 
Participants 
Data were extracted for 12,951 eyes of 11,135 patients receiving a total of 92,976 
ranibizumab injections (Fig 1). The mean age of patients in the database at the time of 
first ranibizumab injection was 78.9 years (range, 55–108 years) for those who 
received unilateral treatment only and 79.5 years (range, 55–98 years) for patients 
who received bilateral treatment at any time during follow-up. The percentage of 
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females was significantly higher in bilateral than in unilateral disease (68.7% vs. 
62.5%; P < 0.001).  
 
There were 8,184 eyes that were treatment-free for at least 3 months. Similarly there 
were 5,134 eyes, 3,522 eyes and 2,452 eyes that were treatment-free for at least 6 
months, 9 months and 12 months respectively.  
 
The OCT data was not analysed as it was out of scope of this study.  
 
Time to retreatment after a pause in therapy 
The Kaplan Meier survival analysis shows the time to retreatment after a pause in 
treatment (Fig 2). The time to retreatment for the 20th centile was 0.58 months in eyes 
with 3-month treatment free interval (TFI), 2.07 months in eyes with 6-month TFI, 
3.69 months in those with 9-month TFI and 5.90 months in eyes with 12-month TFI. 
 
Similarly, the time to retreatment for the 50th centile was 2.54 months in the 3 month 
TFI eyes, 9.62 months in the 6 month TFI eyes, 15.84 months in the 9 month TFI eyes 
and 22.49 months in the 12 month TFI eyes.  
 
Retreatment was noted to occur earlier in eyes that had shown improvement or 
stabilisation of vision with ranibizumab treatment (‘better eyes’ and ‘same vision 
eyes’), when compared to baseline visual acuity prior to loading phase (Fig 3).    
 
Table 1. 
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 Proportion of eyes requiring retreatment by given time point 
 At 3 months 
follow-up 
At 6 months 
follow-up 
At 9 months 
follow-up 
At 12 months 
follow-up 
TFI 3 months  54% 68% 74% 77% 
TFI 6 months 30% 44% 51% 56% 
TFI 9 months 20% 31% 37% 43% 
TFI 12 months 14% 21% 28% 34% 
 
 
Table 1 depicts the percentages of eyes that required retreatment with ranibizumab 
after remaining treatment-free for variable periods. Following a TFI of 3, 6, 9 and 12 
months, 68%, 44%, 31% and 21% of eyes required retreatments after further 6-
months of follow-up respectively. Similarly, after 12-months of follow-up, 77%, 56%, 
43% and 34% of eyes from the same groups required retreatment.  
 
Visual Outcome  
The mean visual acuities at the start of the TFIs and before and after retreatment are 
shown in Table 2. At the time that retreatment was initiated there was a decrease in 
mean VA of 2.93 to 4.25 letters. Although the visual acuity improved with 
retreatment, it did not recover to that recorded at the beginning of TFI, with a mean 
loss of 1.83 to 3.23 ETDRS letters.  
 
Table 2. 
 Mean visual acuity (ETDRS letters) 
 At the beginning 
of treatment-free 
period 
At the time of 
retreatment 
At first visit after 
retreatment 
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TFI 3 months 57.26 54.33 55.43 
TFI 6 months 56.90 53.24 54.32 
TFI 9 months 56.47 52.29 53.44 
TFI 12 months 57.50 53.25 54.27 
 
 
DISCUSSION 
This is the largest study thus far reported in the literature to focus on the likelihood of 
retreatment in eyes with nAMD that have remained treatment-free during the 
maintenance phase of treatment with intravitreal ranibizumab therapy when using a 
PRN posology.  The study provides real-world data that highlight some important 
findings: (1) Differences in time to retreatment in eyes with variable treatment-free 
intervals, with eyes remaining treatment-free for prolonged periods having longer 
intervals before requiring retreatments; (2) Risk of reactivation/retreatment 
irrespective of whether the eye has been injection-free for 3, 6, 9 or 12 months.  
 
In our study, we found that the likelihood of retreatment reduces as the time without 
treatment increases. Following a treatment-free interval of 3, 6, 9 and 12 months, 
68%, 44%, 31% and 21% of eyes required retreatments after further 6-months of 
follow-up respectively. Similarly, after 12-months of follow-up, 77%, 56%, 43% and 
34% of eyes from the same groups required retreatment. It is interesting to note that 
despite remaining treatment-free for 12-months, nearly a third of eyes required 
retreatment within the next year.  
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Our results showed that the time to retreatment for the 20th centile (i.e. 1 in 5 eyes 
requiring retreatment at that time point) was 0.58 months in the 3-month, 2.07 months 
in the 6-month, 3.69 months in the 9-month and 5.90 months in the 12-month 
treatment free groups. This information is useful in guiding clinicians in how to plan 
less frequent follow-ups of patients who have remained treatment-free for longer 
duration or in their choice of retreatment posology. Once eyes remain treatment-free 
for six months, 2-monthly follow-ups appear reasonable. Similarly, 3-monthly follow-
ups may be reasonable once eyes remain treatment-free for 9 months. 
 
In the overburdened NHS setting, where there are acute capacity issues in medical 
retina clinics, patients whose treated eye (s) remain injection-free for 12 months or 
more may not need regular review in dedicated one-stop nAMD clinic (where 
assessment and injections, if required, are given at the same visit) but less frequent 
review in a 2-stop monitoring retina clinics appears reasonable. This could potentially 
allow the clinicians to reduce the burden on eye clinics and plan the nAMD workload 
more efficiently and help guide future PRN and treat and extend treatment intervals 
and strategies. 
 
However, reduction in the frequency of follow-up visits will also reduce the 
opportunities to detect disease early in the fellow, usually better-seeing, eye.[13] 
Since there is frequent involvement of fellow eyes the potential for synchronizing 
both eye treatments may limit the ability to extend visits.[13] One must cautiously 
consider the trade-off between the implications of continued follow-ups on eye clinics 
and the risk of reactivation. 
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Our real-world data suggest that eyes that have remained injection-free for intervals 
of 3-12 months suffer a decline in visual acuity with disease reactivation. Although 
further treatment leads to some visual recovery, the average decrease in acuity was 
1.83 to 3.23 ETDRS letters, as compared to visual acuity at the beginning of 
injection-free period. This may reflect the chronic and inexorable nature of nAMD, as 
also reported in the SEVEN-UP study, in addition to a degree of under or sub-optimal 
treatment in the real-world outside clinical trial conditions.[17]  
 
Previous studies have reported visual and socioeconomic benefits with a ‘treat-and-
extend’ regimen (TER) in the management of nAMD.[7, 18] In TER, patients are 
treated at each visit regardless of disease activity, with the time between visits 
extended gradually if there is no evidence of active nAMD. Rayess et al, have 
recently demonstrated that patients treated with TER showed visual outcomes 
comparable to ANCHOR and PrONTO studies at 24 months of follow-up with 50% 
fewer examinations of patients.[18] In our study, nearly all of the maintenance phase 
treatments were reactive and driven by disease activity as opposed to proactive 
treatment in TER. This was standard practice up to the time of data extraction in 
2012. Considering the higher retreatment rates in eyes that have remained injection-
free for shorter intervals, it appears that TER may have a role in patients who have 
remained injection-free for six months or less on PRN regimen. However, as the 
number of retreatments is less when the patients remain injection-free for longer 
intervals, it appears that TER may lead to excess treatments in such patients compared 
to PRN. Hence, a switch to TER may not be appropriate for eyes that have been stable 
for more than six months.   
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The strengths of this study include the large sample size, the collection of a 
standardised minimum dataset as mandated by the use of an EMR, the reflection of 
routine clinical practice, and the large number of centres involved. Our study reflects 
the real-world practice in the UK and is of relevance to many sites worldwide. A 
weakness of this study is the loss to follow-up of significant numbers of patients over 
time, as is inevitable in a real-world clinical setting, but this is taken into account 
using Kaplan-Meier analysis. Some of the patients may also have been discharged 
from regular follow-up. The treatment-free groups were not exclusive and also we 
cannot exclude treatment with a TER approach during the follow-up, although this 
was not a common practice before the data for this paper was collected in 2012.  
 
In conclusion, this study has shown that, with a longer treatment-free interval, eyes 
with nAMD are less likely to be retreated with ranibizumab when a PRN approach is 
adopted. This information can help clinicians to plan the appropriate follow-up 
interval for eyes with nAMD and help to reduce the load on overburdened eye clinics. 
One should also bear in mind that nearly a third of eyes that have remained injection-
free for 12 months require retreatment within the next 12 months, suggesting that 
ongoing follow-up is still required.  
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Figure legends 
 
Figure 1. Consolidated Standards of Reporting Trials-style diagram showing the 
patients and eyes treated in the study. EMR = electronic medical record; nAMD = 
neovascular age-related macular degeneration; VEGF = vascular endothelial growth 
factor. 
 
Figure 2. A, B, C and D. Kaplan Meier survival analysis in eyes that have remained 
treatment-free for 3 months, 6 months, 9 months and 12 months. 
 
Figure 3: Kaplan Meier survival analysis showing time to retreatment in eyes 
presenting with same, better or worse vision as compared to baseline visual acuity. 
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Table legends 
 
Table 1: Proportion of eyes requiring retreatment after a certain treatment-free 
interval (TFI).  
 
Table 2: Change in mean visual acuity (ETDRS letters). 
